BLFS vs AZTA

For growth investors, BioLife Solutions, Inc.

(BLFS) is the stronger pick with 17. 0% revenue growth year-over-year, versus 3. 6% for Azenta, Inc. (AZTA). Analysts rate BioLife Solutions, Inc. (BLFS) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, BioLife Solutions, Inc.

(BLFS) delivered a total return of -28. 5%, compared to -80. 3% for Azenta, Inc. (AZTA). Over 10 years, the gap is even starker: BLFS returned +1143% versus AZTA's +121. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), BioLife Solutions, Inc.

(BLFS) is the lower-risk stock at 1. 67β versus Azenta, Inc. 's 2. 17β — meaning AZTA is approximately 30% more volatile than BLFS relative to the S&P 500. On balance sheet safety, BioLife Solutions, Inc. (BLFS) carries a lower debt/equity ratio of 3% versus 6% for Azenta, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), BioLife Solutions, Inc.

(BLFS) is pulling ahead at 17. 0% versus 3. 6% for Azenta, Inc. (AZTA). On earnings-per-share growth, the picture is similar: Azenta, Inc. grew EPS 60. 5% year-over-year, compared to 43. 2% for BioLife Solutions, Inc.. Over a 3-year CAGR, BLFS leads at 8. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Azenta, Inc.

(AZTA) is the more profitable company, earning -9. 4% net margin versus -12. 6% for BioLife Solutions, Inc. — meaning it keeps -9. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AZTA leads at -1. 9% versus -12. 6% for BLFS. At the gross margin level — before operating expenses — BLFS leads at 64. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Azenta, Inc.

(AZTA) trades at 23. 4x forward P/E versus 147. 2x for BioLife Solutions, Inc. — 123. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AZTA: 143. 0% to $44. 67.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, BioLife Solutions, Inc.

(BLFS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+1143% 10Y return). Azenta, Inc. (AZTA) carries a higher beta of 2. 17 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BLFS: +1143%, AZTA: +121. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: BLFS is a small-cap high-growth stock; AZTA is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.